Hemispherx BioPharma, Inc (NYSEMKT:HEB), reported that it has executed an agreement with Emerge Health Pty Ltd. (“Emerge”) to seek approval of Alferon N Injection® in Australia and New Zealand and to commence distribution of Alferon in both countries on a named-patient basis, where deemed appropriate. 

Hemispherx and Emerge will collaborate on seeking regulatory approval from Australia’s Therapeutic Goods Administration (“TGA”) and New Zealand’s Medicines and Medical Devices Safety Authority (“Medsafe”).

Under an exclusive license to sell, market, and distribute Alferon N Injection® in Australia and New Zealand, Emerge will implement regulatory-compliant programs to educate physicians about Alferon®. Hemispherx will support these efforts and will supply Alferon® at a predetermined transfer price.

Peter Davey and Chris Rossidis, Co-Founders of Emerge, both said “Having visited Hemispherx upgraded Alferon manufacturing facility and met some of the company’s key people, we are impressed by what we saw and whom we met and believe that Alferon N Injection® represents a significant opportunity in Australia and New Zealand for patients with recurring genital warts and those refractory to recombinant interferon.”

Thomas K. Equels, Executive Vice Chairman and CFO of Hemispherx said “We continue to make progress toward re-launching Alferon N Injection® and are very pleased to be collaborating with Emerge to provide Alferon under these unique access programs and to work with them to gain formal regulatory approval.” (Original Source)

Shares of Hemispherx Biopharma closed yesterday at $0.1851. HEB has a 1-year high of $0.40 and a 1-year low of $0.17. The stock’s 50-day moving average is $0.20 and its 200-day moving average is $0.23.

Hemispherx Biopharma Inc is a specialty pharmaceutical company. It is engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders.